The effect of opportunistic illness on HIV RNA viral load and CD4+ T cell count among HIV-positive adults taking antiretroviral therapy

Journal of the International AIDS Society

Volumn 16, Issue , 2013, Pages

  Ekwaru, John P ^a,b   Campbell, James ^b   Malamba, Samuel ^b   Moore, David M ^c,d   Were, Willy ^b   Mermin, Jonathan ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UGANDA VIRUS RESEARCH INSTITUTE   (Uganda)

^c BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

ART; CD4+ T cell lymphocyte count; HIV; HIV RNA viral load; Opportunistic infections; Uganda

Indexed keywords

COTRIMOXAZOLE; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; STAVUDINE; VIRUS RNA; ANTIRETROVIRUS AGENT;

ADULT; ANTIRETROVIRAL THERAPY; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CRYPTOCOCCAL MENINGITIS; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN TISSUE; KAPOSI SARCOMA; MAJOR CLINICAL STUDY; MALARIA; MALE; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SEX DIFFERENCE; VIRUS LOAD; AIDS RELATED COMPLEX; ART; CD4+ T CELL LYMPHOCYTE COUNT; HIV RNA VIRAL LOAD; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISOLATION AND PURIFICATION; PATHOLOGY; PLASMA; UGANDA; VIROLOGY;

ART; CD4+ T CELL LYMPHOCYTE COUNT; HIV; HIV RNA VIRAL LOAD; OPPORTUNISTIC INFECTIONS; UGANDA;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; PLASMA; RNA, VIRAL; VIRAL LOAD;

MLCS; MLOWN;

EID: 84879190166     PISSN: None     EISSN: 17582652     Source Type: Journal    
DOI: 10.7448/IAS.16.1.17355     Document Type: Article

References (19)

1. Mermin J, Lule JR, Ekwaru JP. Association between malaria and CD4 cell count decline among persons with HIV. J Acquir Immune Defic Syndr. 2006;41(1):129-30.
2. Kublin JG, Patnaik P, Jere CS, Miller WC, Hoffman IF, Chimbiya N, et al. Effect of Plasmodium falciparum malaria on concentration of HIV-1-RNA in the blood of adults in rural Malawi: a prospective cohort study. Lancet. 2005;365(9455): 233-40.
3. Bush CE, Donovan RM, Markowitz NP, Kvale P, Saravolatz LD. A study of HIV RNA viral load in AIDS patients with bacterial pneumonia. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13(1):23-6.
4. Donovan RM, Bush CE, Markowitz NP, Baxa DM, Saravolatz LD. Changes in virus load markers during AIDS-associated opportunistic diseases in human immunodeficiency virus-infected persons. J Infect Dis. 1996;174(2):401-3.
5. Goletti D, Weissman D, Jackson RW, Graham NM, Vlahov D, Klein RS, et al. Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. J Immunol. 1996;157(3):1271-8.
6. Mole L, Ripich S, Margolis D, Holodniy M. The impact of active herpes simplex virus infection on human immunodeficiency virus load. J Infect Dis. 1997;176(3):766-70.
7. Toossi Z, Mayanja-Kizza H, Hirsch CS, Edmonds KL, Spahlinger T, Hom DL, et al. Impact of tuberculosis (TB) on HIV-1 activity in dually infected patients. Clin Exp Immunol. 2001;123(2):233-8.
8. Chaisson RE, Gallant JE, Keruly JC, Moore RD. Impact of opportunistic disease on survival in patients with HIV infection. AIDS. 1998;12(1):29-33.
9. Osmond DH, Chin DP, Glassroth J, Kvale PA, Wallace JM, Rosen MJ, et al. Impact of bacterial pneumonia and Pneumocystis carinii pneumonia on human immunodeficiency virus disease progression. Pulmonary complications of HIV study group. Clin Infect Dis. 1999;29(3):536-43.
10. Jones LE, Perelson AS. Transient viremia, plasma viral load, and reservoir replenishment in HIV-infected patients on antiretroviral therapy. J Acquir Immune Defic Syndr. 2007;45(5):483-93.
11. Weidle PJ, Wamai N, Solberg P, Liechty C, Sendagala S, Were W, et al. Adherence to antiretroviral therapy in a home-based AIDS care programme in rural Uganda. Lancet. 2006;368(9547):1587-94.
12. Ministry of Health, GoU. National antiretroviral treatment guidelines for adults, adolescents, and children. Kampala: Ministry of Health, Government of Uganda; 2009.
13. Fang G, Burger H, Grimson R, Tropper P, Nachman S, Mayers D, et al. Maternal plasma human immunodeficiency virus type 1 RNA level: a determinant and projected threshold for mother-to-child transmission. Proc Natl Acad Sci U S A. 1995;92(26):12100-4.
14. Mofenson LM, Lambert JS, Stiehm ER, Bethel J, Meyer WA 3rd, Whitehouse J, et al. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS clinical trials group study 185 team. N Engl J Med. 1999;341(6):385-93.
15. Orenstein JM, Fox C, Wahl SM. Macrophages as a source of HIV during opportunistic infections. Science. 1997;276(5320):1857-61.
16. Mermin J, Lule JR, Ekwaru JP, Pitter C. Should cotrimoxazole prophylaxis be taken by all adults with HIV in Africa? AIDS. 2005;19(8):845-6.
17. World Health Organization. Guidelines on co-trimoxazole prophylaxis for HIV-related infections among children, adolescents and adults: recommendations for a public health approach. 2006 [cited 2012 Nov 27]. Available from: http://www.who.int/hiv/pub/guidelines/ctxguidelines.pdf
18. Mermin J, Ekwaru JP, Liechty CA, Were W, Downing R, Ransom R, et al. Effect of co-trimoxazole prophylaxis, antiretroviral therapy, and insecticide-treated bednets on the frequency of malaria in HIV-1-infected adults in Uganda: a prospective cohort study. Lancet. 2006;367(9518):1256-61.
19. Campbell JD, Moore D, Degerman R, Kaharuza F, Were W, Muramuzi E, et al. HIV-infected ugandan adults taking antiretroviral therapy with CD4 counts >200 cells/μL who discontinue cotrimoxazole prophylaxis have increased risk of malaria and diarrhea. Clin Infect Dis. 2012;54(8):1204-11.